ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has received an average recommendation of “Buy” from the six brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $6.25.
A number of research analysts have issued reports on the stock. Laidlaw assumed coverage on shares of ZIOPHARM Oncology in a research report on Monday, April 1st. They set a “buy” rating and a $7.50 target price on the stock. BidaskClub upgraded shares of ZIOPHARM Oncology from a “buy” rating to a “strong-buy” rating in a research report on Monday, June 17th. Zacks Investment Research upgraded shares of Zurich Insurance Group from a “sell” rating to a “hold” rating in a research report on Saturday, May 18th. HC Wainwright increased their target price on shares of Palatin Technologies from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Thursday, May 9th. Finally, Lake Street Capital set a $30.00 target price on shares of TheStreet and gave the stock a “buy” rating in a research report on Thursday, April 4th.
Several hedge funds and other institutional investors have recently bought and sold shares of ZIOP. D. E. Shaw & Co. Inc. boosted its position in shares of ZIOPHARM Oncology by 39.7% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 530,108 shares of the biotechnology company’s stock worth $991,000 after acquiring an additional 150,760 shares in the last quarter. Geode Capital Management LLC boosted its position in ZIOPHARM Oncology by 10.3% in the fourth quarter. Geode Capital Management LLC now owns 1,552,016 shares of the biotechnology company’s stock valued at $2,902,000 after buying an additional 145,129 shares in the last quarter. Two Sigma Investments LP acquired a new stake in ZIOPHARM Oncology in the fourth quarter valued at approximately $212,000. Iridian Asset Management LLC CT acquired a new stake in ZIOPHARM Oncology in the first quarter valued at approximately $369,000. Finally, Jane Street Group LLC boosted its position in ZIOPHARM Oncology by 121.5% in the fourth quarter. Jane Street Group LLC now owns 111,224 shares of the biotechnology company’s stock valued at $208,000 after buying an additional 61,012 shares in the last quarter. Institutional investors and hedge funds own 38.75% of the company’s stock.
Shares of NASDAQ:ZIOP traded up $0.02 on Thursday, reaching $5.75. 692,846 shares of the company’s stock were exchanged, compared to its average volume of 1,769,985. The company’s fifty day moving average price is $5.24. ZIOPHARM Oncology has a twelve month low of $1.56 and a twelve month high of $6.30. The firm has a market cap of $909.85 million, a P/E ratio of -11.98 and a beta of 2.66. The company has a quick ratio of 8.89, a current ratio of 8.89 and a debt-to-equity ratio of 0.01.
ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.01. Equities analysts predict that ZIOPHARM Oncology will post -0.33 earnings per share for the current fiscal year.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.
Recommended Story: What is the LIBOR?
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.